Echosens Ranks Among PM360’s Leading Innovative Companies for 9th Annual Innovations Issue, Demonstrates Ingenuity During COVID-19 Pandemic  

WALTHAM, Mass.--(BUSINESS WIRE)--#COVID19--Echosens, a high-technology company offering the FibroScan family of products, is pleased to announce that it has been chosen among the top 12 innovative companies for PM360’s 9^th annual Innovations Issue, which focused on the healthcare industry’s most innovative companies, startups, divisions, products, services and strategies of 2020. Echosens pioneered the field of elastography technology by developing FibroScan, the first device that quantifies liver stiffness non-invasively and painlessly at the point of care.

“Our industry didn’t waste a second in working to address how COVID-19 impacted patients, healthcare professionals and the way companies were forced to operate,” says Anna Stashower, CEO, publisher, and editor-in-chief, PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device and diagnostics industries. “This year’s selections are not just a highlight of our industry’s incredible ingenuity, but also the efficiency and determination they demonstrated in response to a world in crisis. Even though not all of our selections are related to COVID-19, they all show just how hard our industry works to find new, better and quicker ways to improve how the industry operates to better serve patients.”

FibroScan uses a patented technique called VCTE in which a controlled frequency shear wave is mechanically induced to the liver. In 2020, Echosens introduced FibroScan 630 Expert to give clinicians the capability to measure spleen stiffness. Non-invasive assessment of the spleen is an important advancement in assessing portal hypertension (PH), which is the main consequence of cirrhosis and responsible for a majority of its complications. In the western world, the most common etiology of PH is cirrhosis due to alcoholic liver disease, nonalcoholic steatohepatitis (NASH), and hepatitis C infection. According to a recent estimate 15 million people in the United States have alcohol abuse disorder, nearly 88,000 people die annually due to alcohol, 10%-15% of people with alcoholism develop cirrhosis, and another 3 million people have chronic hepatitis C infection, with 25%-28% of these patients developing cirrhosis.

Jon Gingrich, CEO, Echosens North America, says, “We are thrilled to be included in this impressive list of innovators by PM360, a publication that has always recognized how crucial innovation is within this industry. This honor further validates our efforts to provide non-invasive tools that enable clinicians to battle the nation’s liver disease epidemic.”

About Echosens

Echosens, the developer of FibroScan^®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans. For more information, please visit http://www.echosens.us.

Brittany Tedesco
CPR Communications
btedesco@cpronline.com
201.641.1911 x 14